Subcutaneous Epcoritamab in Combination with Rituximab plus Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

被引：11

作者：

Falchi, Lorenzo ^{[1
]}

Leslie, Lori A. ^{[2
]}

Belada, David ^{[3
]}

Kopeckova, Katerina ^{[4
]}

Offner, Fritz ^{[5
]}

Brody, Joshua ^{[6
]}

Canales, Miguel ^{[7
]}

Martin Garcia-Sancho, Alejandro ^{[8
]}

Nijland, Marcel ^{[9
,10
]}

Andersson, P-O ^{[11
]}

Awan, Farrukh T. ^{[12
]}

Christensen, Jacob Haaber ^{[13
]}

Drott, Kristina ^{[14
]}

Hellstrom, Mats ^{[15
]}

Lewerin, Catharina ^{[16
]}

Narkhede, Mayur ^{[17
]}

Snauwaert, Sylvia ^{[18
]}

Wahlin, Bjorn E. ^{[19
]}

Rana, Ali ^{[20
]}

Abbas, Aqeel ^{[20
]}

Wang, Liwei ^{[20
]}

Minh Dinh ^{[21
]}

Vermaat, Joost S. P. ^{[22
]}

Abrisqueta, Pau ^{[23
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

[2] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[3] Charles Univ Prague, Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[4] Fak Nemocnice Motole, Prague, Czech Republic

[5] Univ Ziekenhuis Gent, Ghent, Belgium

[6] Icahn Sch Med Mt Sinai, New York, NY USA

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Salamanca, Salamanca, Spain

[9] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[10] Univ Groningen, Groningen, Netherlands

[11] Sodra Alvsborgs Sjukhus, Boras, Sweden

[12] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[13] Odense Univ Hosp, Odense, Denmark

[14] Skane Univ Hosp, Lund, Sweden

[15] Uppsala Univ Hosp, Uppsala, Sweden

[16] Sahlgrens Univ Hosp, Gothenburg, Sweden

[17] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[18] AZ Sint Jan Brugge, Dept Hematol, Brugge, Belgium

[19] Karolinska Inst, Stockholm, Sweden

[20] Genmab, Princeton, NJ USA

[21] AbbVie Inc, N Chicago, IL USA

[22] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands

[23] Hosp Univ Vall dHebron, Barcelona, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158232

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1471 / 1473

页数：3

共 50 条

[31] A multicenter randomized trial of Fludarabine and Mitoxantrone (FM) plus Rituximab versus CHOP plus Rituximab as first-line treatment in patients with follicular lymphoma (FL).
Zinzani, PL
BLOOD, 2002, 100 (11) : 93A - 93A
[32] Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma
Hill, Brian T.
Chen, Yanwen
Jagadeesh, Deepa
Dean, Robert
Koc, Omer
Boughan, Kirsten
Cooper, Brenda
Pohlman, Brad
Caimi, Paolo
Smith, Mitchell R.
LEUKEMIA & LYMPHOMA, 2024, 65 (06) : 768 - 773
[33] Subcutaneous Epcoritamab Combined With R-CHOP for First-Line Treatment of Patients With High-Risk Diffuse Large B-Cell Lymphoma: Phase 1/2 Update
Lorenzo, Falchi
Fritz, Offner
David, Belada
Joshua, Brody
Linton, Kim M.
Yasmin, Karimi
Raul, Cordoba
Sylvia, Snauwaert
Aqeel, Abbas
Liwei, Wang
Jun, Wu
Brian, Elliott
Clausen, Michael R.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S30 - S30
[34] Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial
Flinn, Ian W.
Mainwaring, Mark
Peacock, Nancy
Shipley, Dianna
Arrowsmith, Edward
Savona, Michael R.
Hainsworth, John D.
Berdeja, Jesus G.
BLOOD, 2012, 120 (21)
[35] First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab plus /- nivolumab: An umbrella randomised phase 2 investigator-led study.
Chong, Geoffrey
Palmer, Jodie
Barraclough, Allison
Churilov, Leonid
Keane, Colm
Lee, Sze Ting
Lee, Denise
Ratnasingam, Sumita
Smith, Charmaine
Hawkes, Eliza Anne
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance.
Andorsky, David Jacob
Franson, Paula J.
Mouro, Jorge L.
Li, Jiahui
Foon, Kenneth A.
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[37] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS
Sabater, E.
Rueda, A.
Salar, A.
Lopez-Guillermo, A.
Oyagueez, I.
Collar, J. M.
HAEMATOLOGICA, 2014, 99 : 487 - 488
[38] SAFETY AND EFFICACY OF RITUXIMAB AND CHLORAMBUCIL IN COMBINATION AS FIRST-LINE TREATMENT IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS
Martinelli, G.
Andreola, G.
Laszlo, D.
Minga, P.
Cannella, L.
Liptrott, S.
Sammassimo, S.
Linetti, M.
Calabrese, L.
Bassi, S.
HAEMATOLOGICA, 2012, 97 : 651 - 652
[39] Magnify: A Phase IIIB Trial Shows Promising Efficacy in the Treatment of Relapsed/Refractory, Indolent Non-Hodgkin Lymphoma Patients with Lenalidomide in Combination with Rituximab (R2)
Rummer, Mathias
Andorsky, David J.
Schmidt, Burkhard
La Rosee, Paul
Graeven, Illtrich
Czuczman, Myron
Llorente, Mary
Li, Jiahui
Sharman, Jeff
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 238 - 238
[40] MAGNIFY: A phase IIIb trial shows promising efficacy in the treatment of relapsed/refractory, indolent non-Hodgkin lymphoma patients with lenalidomide in combination with rituximab (R2)
Burchardt, A.
Andorsky, D. J.
Schmidt, B.
La Rosee, P.
Graeven, U.
Czuczman, M.
Llorente, M.
Li, J.
Sharman, J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 160 - 161

← 1 2 3 4 5 →